NCT00238121 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 40
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 56
- units
- Participants
- groups
- description
- Patients with advanced uterine carcinoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- BG000
- title
- Carcinoma
- description
- Patients with advanced uterine carcinosarcoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- BG001
- title
- Carcinosarcoma
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 44
- upper Limit
- 83
- value
- 64
- group Id
- BG001
- lower Limit
- 40
- upper Limit
- 87
- value
- 64
- group Id
- BG002
- lower Limit
- 40
- upper Limit
- 87
- value
- 64
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Customized
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 40
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 56
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 29
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 39
- title
- Non-Hispanic white
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 5
- title
- Hispanic
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 5
- title
- African-American
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 7
- title
- Asian
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 12
- title
- Adenocarcinoma (unspecified)
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- title
- Serous
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Clear cell
- categories
- measurements
- group Id
- BG000
- value
- 24
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 24
- title
- Endometrioid
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 16
- title
- Carcinosarcoma
- param Type
- NUMBER
- title
- Histology
- unit Of Measure
- participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 40
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 56
- units
- Participants
- groups
- description
- Patients with advanced uterine carcinoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- BG000
- title
- Carcinoma
- description
- Patients with advanced uterine carcinosarcoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- BG001
- title
- Carcinosarcoma
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 44
- upper Limit
- 83
- value
- 64
- group Id
- BG001
- lower Limit
- 40
- upper Limit
- 87
- value
- 64
- group Id
- BG002
- lower Limit
- 40
- upper Limit
- 87
- value
- 64
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Customized
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 40
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 56
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 29
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 39
- title
- Non-Hispanic white
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 5
- title
- Hispanic
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 5
- title
- African-American
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 7
- title
- Asian
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 12
- title
- Adenocarcinoma (unspecified)
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- title
- Serous
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Clear cell
- categories
- measurements
- group Id
- BG000
- value
- 24
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 24
- title
- Endometrioid
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 16
- title
- Carcinosarcoma
- param Type
- NUMBER
- title
- Histology
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle